C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

This company is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of +49.3%. Revenues are expected to be $6.88 million, up 158.7% from the year-ago quarter. C4 Therapeutics, Inc. (CCCC) shares rallied 13.7% in the last trading session to close at $7.38. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 56.8% gain over the past four weeks. The sud ...